From: Impact of dopamine-related genetic variants on physical activity in old age – a cohort study
Total sample | 66 years | 81–87 years | ||||
---|---|---|---|---|---|---|
DRD1 genotype | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
TT (lower efficacy) | 32.7 (26.6, 38.7) | 30.5 (23.3, 37.7) | 38.8 (34.7, 42.9) | 36.6 (28.4, 44.9) | 14.8 (10.1, 19.6) | 15.2 (8.2, 22.1) |
CT (intermediate efficacy) | 37.7 (31.6, 43.8) | 32.7 (27.9, 37.5) | 39.8 (36.1, 43.5) | 32.1 (24.1, 40.2) | 23.1 (18.9, 27.3) | 24.5 (17.7, 31.3) |
CC (higher efficacy) | 39.8 (32.4, 47.2) | 49.9 (40.8, 59.0) | 40.8 (33.9, 47.8) | 52.1 (40.3, 63.8) | 27.2 (19.5, 34.9) | 35.8 (26.8, 44.8) |
TT vs. CC (p-value) | 0.043 | 0.001 | 0.626 | 0.036 | 0.007 | 0.000 |
TT vs. CT (p-value) | 0.041 | 0.618 | 0.727 | 0.442 | 0.012 | 0.064 |
CT vs. CC (p-value) | 0.538 | 0.001 | 0.798 | 0.007 | 0.354 | 0.049 |